NATCO Pharma (NATCOPHARM) announced its Q2 FY26 results, reporting a consolidated total revenue of ₹1,463.0 Crore, up from ₹1,434.9 crore in Q2 FY25. EBITDA reached ₹679.2 Crore with margins at 46.4%. The company also declared an interim dividend of ₹1.5 per equity share. Additionally, NATCO completed the acquisition of 35.75% of Adcock Ingram Holdings for USD 225 million.
Financial Performance
NATCO Pharma announced its results for Q2 FY26, reporting a consolidated total revenue of ₹1,463.0 Crore compared to ₹1,434.9 crore in Q2 FY25. The company’s EBITDA (including other income) for the quarter stood at ₹679.2 Crore, showcasing margins of 46.4%. The consolidated net profit for the period was ₹517.9 Crore.
Segmental Revenue Breakdown
The revenue split across different segments is as follows:
- Active Pharmaceutical Ingredients (API): ₹53.9 Crore
- Domestic Formulations: ₹105.4 Crore
- Formulations export (Incl. profit share and subs): ₹1,147.0 Crore
- Crop Health Sciences (CHS): ₹52.4 Crore
- Other operating and non-operating income: ₹104.3 Crore
Dividend Announcement
The Board of Directors have declared an interim dividend of ₹1.5 per equity share of ₹2 each during Q2 FY26.
Strategic Developments
On November 11, 2025, NATCO Pharma South Africa Proprietary Limited completed the acquisition of 35.75% of Adcock Ingram Holdings Limited for a total purchase consideration of ZAR 3,873 million (USD 225 million). The Board granted approval to evaluate the demerger of the Company’s Agro Chemicals business into a separate legal entity, optimizing the capital and shareholding structure.
Source: BSE